tumor necrosis factor inhibitors

Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial
Fabian Proft, Murat Torgutalp, Burkhard Muche, Valeria Rios Rodriguez, Joachim Listing, Mikhail Protopopov, Judith Rademacher, Hildrun Haibel, Laura Spiller, Anne-Katrin Weber, Maryna Verba, Jan Brandt-Juergens, Uta Kiltz, Maren Sieburg, Swen Jacki, Joachim Sieper, Denis Poddubnyy

Annals of the Rheumatic Diseases May 2024, 83 (5) 599-607; DOI: 10.1136/ard-2023-224699
Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis
Joshua F Baker, James R ODell, Bryant R England, Jon T Giles, Jefferey A Newcomb, Michael D George, Geoffrey Thiele, Larry Moreland, S Louis Bridges, Jeffrey R Curtis, Ted R Mikuls

Annals of the Rheumatic Diseases Apr 2024, 83 (4) 429-436; DOI: 10.1136/ard-2023-225014
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
Marcin Stajszczyk, Izabela Obarska, Slawomir Jeka, Bogdan Batko

Annals of the Rheumatic Diseases Sep 2023, 82 (9) 1171-1180; DOI: 10.1136/ard-2022-223696
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
Lars Erik Kristensen, Silvio Danese, Arne Yndestad, Cunshan Wang, Edward Nagy, Irene Modesto, Jose Rivas, Birgitta Benda

Annals of the Rheumatic Diseases Jul 2023, 82 (7) 901-910; DOI: 10.1136/ard-2022-223715
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
Benjamin de Valence, Marion Delaune, Yann Nguyen, Vincent Jachiet, Mael Heiblig, Alexis Jean, Stanislas Riescher Tuczkiewicz, Pierrick Henneton, Philippe Guilpain, Nicolas Schleinitz, Guillaume Le Guenno, Hervé Lobbes, Valentin Lacombe, Samuel Ardois, Estibaliz Lazaro, Vincent Langlois, Roderau Outh, Julien Vinit, Jean-Philippe Martellosio, Paul Decker, Thomas Moulinet, Yannick Dieudonné, Adrien Bigot, Louis Terriou, Alexandre Vlakos, Baptiste de Maleprade, Guillaume Denis, Jonathan Broner, Marie Kostine, Sebastien Humbert, Francois Lifermann, Maxime Samson, Susann Pechuzal, Achille Aouba, Olivier Kosmider, Jeremie Dion, Sylvie Grosleron, Rim Bourguiba, Benjamin Terrier, Sophie Georgin-Lavialle, Olivier Fain, Arsène Mekinian, Marjolaine Morgand, Thibault Comont, Jerome Hadjadj

Annals of the Rheumatic Diseases Mar 2024, 83 (3) 372-381; DOI: 10.1136/ard-2023-224819
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
Murat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, Fabian Proft, Mikhail Protopopov, Maryna Verba, Judith Rademacher, Hildrun Haibel, Joachim Sieper, Martin Rudwaleit, Denis Poddubnyy

Annals of the Rheumatic Diseases Sep 2022, 81 (9) 1252-1259; DOI: 10.1136/annrheumdis-2022-222324
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Kim Lauper, Michele Iudici, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, René Cordtz, Diederik De Cock, Lene Dreyer, Ori Elkayam, Ellen-Margrethe Hauge, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun Inanc, Lianne Kearsley-Fleet, Eirik Klami Kristianslund, Tore K Kvien, Burkhard F Leeb, Galina Lukina, Dan C Nordström, Karel Pavelka, Manuel Pombo-Suarez, Ziga Rotar, Maria Jose Santos, Anja Strangfeld, Patrick Verschueren, Delphine Sophie Courvoisier, Axel Finckh

Annals of the Rheumatic Diseases Oct 2022, 81 (10) 1358-1366; DOI: 10.1136/annrheumdis-2022-222586
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Stavland Lexberg, Tor Magne Madland, Hallvard Fremstad, Christian A. Høili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger Myrnes Hansen, Ellen Moholt, Till Uhlig, Daniel H Solomon, Désirée van der Heijde, Tore K Kvien, Espen A Haavardsholm

Annals of the Rheumatic Diseases Nov 2023, 82 (11) 1394-1403; DOI: 10.1136/ard-2023-224476
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B Shapiro, Janet E Pope, Hendrik Schulze-Koops

Annals of the Rheumatic Diseases Nov 2022, 81 (11) 1491-1503; DOI: 10.1136/ard-2022-222405
EULAR 75-year anniversary: commentaries on ARD papers from 25 years ago
Kimme L Hyrich

Annals of the Rheumatic Diseases Dec 2022, 81 (12) 1625-1627; DOI: 10.1136/ard-2022-222585

Main menu

tumor necrosis factor inhibitors

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

tumor necrosis factor inhibitors

Pages